UPDATED Apr 05, 2024
Well rounded companies, with acceptable leverage, projected to deliver an ROE north of 20% in three years.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
NATCOPHARM | ₹997.30 | 4.8% | 72.5% | ₹178.6b | ₹930.82 | PE14x | E14.3% | 1.0% | Pharmaceuticals & Biotech | ||
BFT | zł2,830.00 | 0% | 148.2% | zł8.4b | zł2,750.00 | PE19x | E9.2% | 1.4% | Commercial Services | ||
LEHN | CHF1,672.00 | -2.0% | -15.8% | CHF1.9b | CHF2,113.25 | PE25.2x | E9.9% | 3.1% | Tech | ||
6028 | JP¥2,925.00 | -5.6% | -14.6% | JP¥312.5b | JP¥3,865.71 | PE19.2x | E9.7% | 2.6% | Commercial Services |